Acetyl Gastric Inhibitory Peptide (human) (TFA) (Synonyms: Human N-acetyl GIP TFA) |
| カタログ番号GC68604 |
Acetyl Gastric Inhibitory Peptide (human) (TFA)は合成の、化学修飾されたヒト胃抑制ペプチドである。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 299898-52-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Acetyl Gastric Inhibitory Peptide (human) (TFA)は合成の、化学修飾されたヒト胃抑制ペプチドである[1]。Acetyl Gastric Inhibitory Peptide (human) (TFA) は、生理学的インクレチンホルモンであり、インスリンの放出をグルコース依存的に効果的に刺激できる[2]。Acetyl Gastric Inhibitory Peptide (human) (TFA)は、代謝疾患の研究と糖尿病薬剤の開発によく使われている[3-4]。成体した雄のwistarラットで、Acetyl Gastric Inhibitory Peptide (human) (TFA) (25nM/kg；腹腔内注射；単回注射)は、血漿グルコース濃度を著しく減らす[5]。
References:
[1]. Flatt PR, O'harte FP, Utech Ltd. Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function. United States patent application US 11/991,638. 2009 Nov 19.
[2]. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia. 2009 Sep; 52: 1724-1731.
[3]. Bailey CJ. GIP analogues and the treatment of obesity-diabetes. Peptides. 2020 Mar; 125: 170202.
[4]. O'Harte F, Gault V, Parker J, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002 Sep; 45: 1281-1291.
[5]. Cassidy RS, Irwin N, Flatt PR. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets. Biological chemistry. 2008 Feb; 389(2): 189-193.
| 動物実験 [1]: | |
動物モデル | 成体した雄のwistarラット |
準備方法 | 生理食塩水(0.9%, w/v, NaCl)またはグルコース[体重1kgあたりに18 mmol(b.w.)]のみ、または天然胃抑制ペプチド(GIP)、GLP-1、アセチル胃抑制ペプチド(ヒト) (TFA)、GIP(Lys37)PAL、N-AcGIP(Lys37)PAL、(Pro3)GIP or (Pro3)GIP+GIP (用量は全て25nM/kg b.w.)との併用で、腹腔内注射した後、血漿グルコースと血清グルカゴンの反応を評価した。 |
投与形態 | 25nM/kg；腹腔内；単回注射 |
アプリケーション | アセチル胃抑制ペプチド(ヒト) (TFA)は、血漿グルコースの濃度を著しく減らす。 |
References: | |
| Cas No. | 299898-52-5 | SDF | |
| 同義語 | Human N-acetyl GIP TFA | ||
| Formula | C228H340N60O67S.C2HF3O2 | M.Wt | 5139.62 |
| 溶解度 | H2O : 50 mg/mL (9.73 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 194.6 μL | 972.8 μL | 1.9457 mL |
| 5 mM | 38.9 μL | 194.6 μL | 389.1 μL |
| 10 mM | 19.5 μL | 97.3 μL | 194.6 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *